Inside the CMC Black Box: A Deep Dive with Reza Oliyai

What exactly is CMC — and why is it behind more FDA rejections than any other category?

In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Reza Oliyai, former SVP of Pharmaceutical & Biologics Operations at Gilead Sciences, and now Founder & CEO of Oliyai Consulting, to demystify the world of Chemistry, Manufacturing, and Controls (CMC).

With over three decades of experience and a role in advancing 200+ drug candidates and 27 product launches, Reza offers a front-row seat to what goes wrong — and right — in the drug development journey.

What CMC really means — and why the "controls" part is most overlooked

Why 74% of FDA complete response letters involve CMC issues

The pitfalls of the “Phase 1 mentality” in late-stage development

AI in CMC: helpful tool or overhyped distraction?

How to evaluate CDMO partners (and why big pharma’s pick might be your wrong fit)

The evolving geopolitical landscape and its impact on global manufacturing

What startups, investors, and boards need to understand about CMC before it’s too late

Career advice: what it takes to lead in this increasingly complex field

“CMC is a black box to most executives. That’s a problem. Because it’s also the number one reason drugs get delayed.” — Dr. Reza Oliyai

Whether you're in manufacturing, regulatory, executive leadership, or just trying to understand what actually gets a drug to market — this episode is a must-listen.

Oliyai Consulting

FDA’s recent publication of Complete Response Letters

Dr. Reza Oliyai is a globally recognized leader in pharmaceutical operations, with deep expertise across small molecules, biologics, ADCs, peptides, siRNA, and more. After 28 years at Gilead Sciences, he now advises over 100 organizations worldwide through his firm, Oliyai Consulting.